Gemina Laboratories Ltd. announced the appointment of Brian Firth, an accomplished diagnostic industry executive, as the company's new Chief Executive Officer. The company announced the appointment of founding CEO John Davies, as Chairman of the Board of Directors. The appointment of Mr. Firth follows a multi month process initiated by the Board and current executive team to identify candidates with specific industry experience and proven capabilities to lead Gemina's development, as it transitions from a wholly R&D focused company into a revenue and growth-oriented business.

Brian Firth brings to Gemina an enviable career, focused on health-tech, specifically Point-of-Care diagnostics. He is an accomplished executive with extensive international experience in the sector. Brian spent nearly 8 years at Swiss Precision Diagnostics.

Brian acted as Managing Director of Swiss Precision Diagnostics' UK subsidiary before becoming Chief Operating Officer of Swiss Precisions Diagnostic GmbH (the parent company) in Geneva Switzerland. At Swiss Precision, Brian was responsible for a broad range of business processes including quality management, human resources, regulatory affairs, customer service and research leadership. Prior to his time at Swiss Precision, Brian was a management consultant for Coopers and Lybrand, working with a blue-chip client roster before he established his own advisory practice focused on health-tech and speciality chemistry businesses, working with companies such as AGFA, Johnson & Johnson, Akzo Nobel and Inverness Medical, where he played a key role in establishing the business that was sold to Johnson & Johnson for $1.3 billion.

Subsequently, he founded The Health Works Ltd. (a specialist operations consultancy) that was eventually sold to GE Healthcare. His career has also included time in the human wellness market, particularly human performance monitoring for applications in sports medicine and workplace diagnostics.